90 -12 (50) 2022 — Nabieva D.A., Shiranova Sh. A., — IN THE PHARMACOTHERAPY OF GOUT – MODERN APPROACHES

IN THE PHARMACOTHERAPY OF GOUT – MODERN APPROACHES

Nabieva D.A. Tashkent Medical Academy

Shiranova Sh. A. Tashkent Medical Academy

Muhammadieva S. M. Tashkent Medical Academy

Rezume

The article discusses modern approaches to the treatment of gout, presented in foreign and domestic clinical guidelines. Although the use of urate-lowering therapy for gout is a necessary and highly effective strategy, the benefits of this approach for asymptomatic hyperuricemia are unclear. The safety and efficacy of colchicine, as well as its cardioprotective properties, have been reported in patients with gout and cardiovascular disease. Comparative data on the safety and efficacy of the main urate-lowering drugs allopurinol and febuxostat are presented. According to recent studies, febuxostat is more effective than allopurinol in normalizing serum uric acid levels, is not inferior to it in terms of cardiac safety, and is characterized by a low incidence of other adverse reactions.

Keywords: podagra; colchicine; febuxostat; allopurinol; hyperuricemia; chronic kidney disease; risk factors; cardiovascular diseases.

First page

512

Last page

519

For citation: Nabieva D.A., Shiranova Sh. A., Muhammadieva S. M.– IN THE PHARMACOTHERAPY OF GOUT – MODERN APPROACHES //New Day in Medicine 12(50)2022 512-519 https://clck.ru/33DWPG

LIST OF REFERENCES:

  1. Podagra. Klinik ko’rsatmalar, 2018 [Gout. Klinik tavsiyalar, 2018]. http://cr.rosminzdrav.ru/recomend/251_1
  2. Smit E., Hoy D., Cross M. va boshqalar. Podagraning global yuki: Global kasallik yuki 2010 tadqiqotidan olingan hisob-kitoblar. //Ann Rheum Dis. 2014 yil avgust;73(8):1470-6. doi: 10.1136/annrheumdis-2013-204647
  3. Elfishawi M.M., Zleik N., Kvrgic Z. va boshqalar. Podagra bilan kasallanishning ortib borishi va komorbidiyalarning ortib borayotgan yuki: 20 yil davomida aholiga asoslangan tadqiqot. J Revmatol. 2018 yil aprel;45(4):574-9. doi: 10.3899/jrheum.170806
  4. Galushko E.A., Nasonov E.L. Rossiyada revmatik kasalliklarning tarqalishi. Klinik tibbiyot almanaxi. 2018;46(1):32-9. [Galushko EA, Nasonov E.L. Rossiyada revmatik kasalliklarning tarqalishi. Al’manax klinicheskoi meditsiny. 2018;46(1):32-9. (Rus tilida)].
  5. Zhu Y., Bhavik J., Pandya B.J. va boshqalar. AQShning umumiy aholisida podagra va giperurikemiyaning tarqalishi: Milliy salomatlik va ovqatlanish bo’yicha tadqiqot 2007-2008. Artrit reum. 2011 yil oktabr;63(10):3136- 41. doi: 10.1002/art.30520
  6. Li Q., Li X., Vang J. va boshqalar. Giperurikemiya va podagra diagnostikasi va davolash: klinik amaliyot ko’rsatmalari va konsensus bayonotlarini tizimli ko’rib chiqish. BMJ ochiq. 2019; 9: e026677. doi: 10.1136/ bmjopen-2018- 026677
  7. Kuo C.F., Grainge M.J., Mallen C. va boshqalar. Buyuk Britaniyada podagra yuki ortib bormoqda, ammo davom etayotgan suboptimal davolash: butun mamlakat bo’ylab aholini o’rganish. //Ann Rheum Dis. 2015 yil aprel; 74(4):661-7. doi: 10.1136/annrheumdis- 2013-204463. EPub 2014 yil 15 yanvar.
  8. Richette P., Doherty M., Pascual E. va boshqalar. 2018-yilda revmatizmga qarshi Yevropa ligasi podagra tashxisi uchun dalillarga asoslangan tavsiyalarni yangiladi. //Ann Rheum Dis. 2020 yil yanvar;79(1):31-8. doi: 10.1136/ annrheumdis-2019-215315. Epub 2019, 5-iyun.
  9. Richette P., Doherty M., Pascual E. va boshqalar. 2016 yilda yangilangan EULAR podagrani davolash bo’yicha dalillarga asoslangan tavsiyalari. //Ann Rheum Dis. 2017 Yanvar; 76 (1): 29-42.doi: 10.1136 / annrheumdis-2016-209707. Epub 2016 yil 25 iyul.
  10. Ni Q., Lu X., Chen C. va boshqalar. Giperurikemiya rivojlanishi uchun xavf omillari. //Tibbiyot(Baltimor).2019Okt;98(42):e17597.doi: 10.1097/MD.000000000017597.
  11. Konta T., Ichikawa K., Kawasaki R. va boshqalar. Sarumdagi siydik kislotasi darajasi va o’lim darajasi o’rtasidagi bog’liqlik: umummilliy jamoaga asoslangan kohort tadqiqoti. //Sci Rep. 2020, 8-aprel; 10(1):6066. doi: 10.1038/s41598-020-63134-0
  12. Efstathiadou A., Gill D., McGrane F. va boshqalar. Genetik jihatdan aniqlangan urik kislotasi va yurak-qon tomir va neyrovaskulyar kasalliklar xavfi: tasodifiy sinovlarda o’rganilgan natijalarni Mendelian tasodifiy o’rganish. J Am Heart Dots. 2019 yil 3-sentabr;8(17):e012738. doi: 10.1161/JAHA.119.012738. EPub 2019 yil 23-avgust.
  13. Chazova I.E., Jhernakova Q.K., Kisliak O.A. va boshqalar. Giperurikemiya va yuqori yurak-qon tomir xavfi bo’lgan bemorlar bo’yicha konsensus. //Tizimli gipertenziya. 2019;4(16):8-21. doi: 10.26442/2075082X.2019.4.190686
  14. Yokose C., Lu N., Xie H. va boshqalar. Yurak kasalligi va allopurinol bilan bog’liq jiddiy teri salbiy reaktsiyalari xavfi: umumiy populyatsiyaga asoslangan kohort tadqiqoti. //CMAJ. 2019 yil 30-sentabr;191(39):E1070-E1077. doi: 10.1503/ cmaj.190339
  15. Brucatoa A., Ciancib F., Carnovale C. Asemptomatik bemorlarda giperurikemiyani boshqarish: tanqidiy baholash. //Eur J Intern Med. 2020 yil aprel;74:8-17. doi: 10.1016/ j.ejim.2020.01.001. EPub 2020, 15-yanvar.
  16. Kuo C.F., Grainge M.J., Mallen C. va boshqalar. Buyuk Britaniyada podagra yuki ortib bormoqda, ammo davom etayotgan suboptimal davolash: butun mamlakat bo’ylab aholini o’rganish. //Ann Rheum Dis. 2015 yil aprel; 74(4):661-7. doi: 10.1136/annrheumdis- 2013-204463
  17. Choi H.K., Soriano L.C., Zhang Y. va boshqalar. Gipertenziv dorilar va gipertenziya bilan og’rigan bemorlarda gut xavfi: populyatsiyaga asoslangan vaziyatni nazorat qilish. //BMJ. 2012 yil 12 yanvar;344:d8190. doi: https: 10.1136/bmj.d8190
  18. Reboussin D.M., Allen N.B., Griswold M.E. va boshqalar. 2017 yilgi ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH uchun tizimli sharh /ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.Circulation. 2018 Oct 23;138(17):e595-e616. doi: 10.1161/CIR.0000000000000601
  19. FitzGerald J.D., Dalbeth N., Mikuls T., et al. 2020 American College of Rheumatology Guideline for the Management of Gout. Arthritis Care Res (Hoboken). 2020 Jun;72(6):744-60.  doi:  10.1002/acr.24180. Epub 2020 May 11.
  20. Yu J., Qiu Q., Liang L., et al. Prophylaxis of acute flares when initiating febuxostat for chronic gouty arthritis in a real-world clinical setting. Mod Rheumatol. 2018 Mar;28(2):339-44. doi:10.1080/14397595.2017.1318467

file

download